Hideyuki Mishima

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto et al. · The Lancet Oncology · 2013 · 252 citations

Oncology, Randomised Phase 3, Bevacizumab Versus S-1 +8

Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: Final results of JCOG0205

Yasuhiro Shimada, Tetsuya Hamaguchi, Junki Mizusawa et al. · European Journal of Cancer · 2014 · 117 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +8

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy

Toru Kono, Taishi Hata, Satoshi Morita et al. · Cancer Chemotherapy and Pharmacology · 2013 · 105 citations · Full text

Level of arterial ligation in sigmoid colon and rectal cancer surgery

Koji Yasuda, Kazushige Kawai, Soichiro Ishihara et al. · World Journal of Surgical Oncology · 2016 · 96 citations · Full text

Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis

Chu Matsuda, Yoshinori Munemoto, Hideyuki Mishima et al. · Cancer Chemotherapy and Pharmacology · 2015 · 80 citations · Full text